Skip to main content

Home/ Health and Fitness Club/ Group items tagged Novel

Rss Feed Group items tagged

1More

Pharmacist Patel Role In new Treatment Trial for Covid-19 - 0 views

  •  
    Community pharmacy is at the heart of one of the most ambitious clinical trials ever undertaken by the UK's primary care network, says senior academic pharmacist Professor Mahendra Patel. The PANORAMIC trial has been designed to rapidly evaluate several antiviral treatments over time that could help people at high risk of Covid-19 recover sooner, prevent the need for hospital admission and so ease the burden on the NHS. The Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC) is a national priority trial led by Oxford University's Primary Care Clinical Trials Unit. Lead investigators say the study will enable early and rapid testing of novel antiviral agents and help repurpose existing drugs against Covid-19. As soon as the trial is set up for delivery, it will be open to eligible participants from across the UK. Prof Patel, a key member of the trial's core team, said: "I'm really excited with this news and also by the prospect that there is a huge potential for pharmacy teams to help play a vital role in supporting this highly ambitious trial, as they have with the PRINCIPLE trial, now the world's largest community based clinical trial for Covid19."
1More

Does Laser Tattoo Removal Work, and is it Dangerous? - 0 views

  •  
    The short answer - yes! A novel laser called a Q-Switched laser gives momentous results to basically help or clear most tattoo inks. The laser tattoo removal treatment in Dubai, Abu Dhabi is protected and convincing and does not impact the including skin. It is a non-prominent response for having tattoos ousted deliberately.
1More

Top 20 Healthcare Solution Providers - Insightscare - 0 views

  •  
    Insights Care is honored to present "The 20 Leading Healthcare Solution Providers 2017" which are adapting novel technologies to meet and exceed the health care standard. We have, on our cover, Validic - a cloud-based platform and the market leader in health data connectivity that provides healthcare organizations access to personal health data, gathered from FDA-listed in-home medical devices, wearables and healthcare apps. Led by company's CEO and co-founder, Drew Schiller, Validic serves as a technical partner and strategic advisor, guiding its clients through digital health data integration and innovation. At Validic, Drew leads corporate strategy, drives key initiatives and works closely with senior executives at partner organizations to stay ahead of the technology curve. He believes that digital health will reshape healthcare.
1More

Breakthrough biomarker blood test for ovarian cancer on the horizon - 1 views

  •  
    The majority of women who undergo surgery for suspected ovarian cancer do not actually have the disease, but these unnecessary surgeries could soon be reduced thanks to a novel blood test developed by a Swedish research team.
1More

NHS :New training to expand role of pharmacy technician - 0 views

  •  
    The NHS plans to train hundreds of pharmacy staff, expanding their ability to provide advanced clinical services and assume wider roles in dispensing medicines. With a targeted launch in September, up to 840 pharmacy technicians can join in the training programme. The online modules will cover consultation skills, therapeutics, clinical decision-making, assessment skills, and service improvement. "Community pharmacies are pivotal in local communities, and this novel training scheme empowers them to extend their service offerings to a wider patient base," said Health Minister Neil O'Brien. "Through our investment in the workforce, we're bolstering the implementation of the Pharmacy First initiative with £645 million, ensuring patients have access to expert assistance for various common ailments, including urinary tract infections and earaches." NHS said the training will offer flexibility to align with the working schedules and prior experience of community pharmacy technicians. It will combine independent online e-course study, educational supervision, and clinical skills training. Facilitated workshops will concentrate on enhancing clinical assessment skills and applying knowledge and skills through case studies, practice activities, and group discussions.
1More

GPhC to recruit five new council members in the next 2 years - 0 views

  •  
    The General Pharmaceutical Council is in the process of appointing five new council members within the next two years, coinciding with the conclusion of the current members' terms. The regulator aims to recruit five individuals from diverse professional and personal backgrounds for its governing council, the GPhC has said. "We are seeking three members to join us in April 2024 and two in April 2025," said GPhC in its job advertisement brief. "For the 2024 intake, two of the new council members must be lay members of the public, while one must be a Saxton . Moreover, at least one out of the three must primarily reside or work wholly or mostly in Wales. As for the new members commencing in 2025, one must be a lay member, and the other must be a registrant member." The members will be initially appointed for a three-year term, with the option to extend their position for a maximum of eight years, GPhC added. The council, which serves as the regulator's governing body, currently comprises 14 members. Half of the council consists of lay members, who bolster public confidence and infuse novel viewpoints into the GPhC, as highlighted by the regulator. "This council will play a pivotal role in shaping the regulatory body's future strategic goals," the regulator added. "These members must contribute positively to patients and society, ensuring the benefits of secure and efficient pharmacy care."
1More

Nivedita Valentine:Pharmanovia appoints as VP - 0 views

  •  
    The life cycle management company, Pharmanovia, has appointed Nivedita Valentine as associate vice president of Product Innovation. Ms Valentine will oversee the company's product innovation operations and decision-making as Pharmanovia continues to focus efforts on both, identifying new prospects to enhance lifecycle management of its brands through incremental innovation. She will report to interim chief scientific officer Stephen Deacon and help bridge unmet patient needs with the help of novel therapies, originating both from in-house development and through partnerships. Ms Valentine currently holds positions on the value-added medicines committee within Medicines for Europe and the International Rare Diseases Research Consortium (IRDiRC) Task Force on Drug Repurposing Guidebook. Pharmanovia CEO Dr James Burt commented: "Digitalisation and utilising the latest technological innovation are notable areas of acceleration within the pharma industry and Nivedita's appointment will ensure iconic brands will continue to be improved, supported, and used sustainably.
1More

Omicron booster:UK autumn Covid vaccination campaign - 0 views

  •  
    Britain's Covid booster campaign is set to kick off this September, after the country became the first in the world to approve an Omicron-adapted shot. Around 26 million people in Britain are estimated to be eligible for an autumn Covid-19 booster, having had at least two Covid vaccine doses already, a UK Health Security Agency (UKHSA) spokesperson said. The preference is to deploy what is known as a "bivalent vaccine" that targets both the original virus and the Omicron variant through the autumn campaign, but that will depend on the health regulator (MHRA) approving such shots and the state of vaccine supplies. The UK's Joint Committee on Vaccination and Immunisation (JCVI) has advised boosters should be given to over-50s, individuals in clinical risk groups, frontline workers and care-home staff ahead of the winter, when respiratory viruses are typically at their peak. On Monday (August 15), the MHRA gave Moderna's bivalent shot conditional approval. The endorsement of the vaccine is based on data that showed it produced a marginally better immune response against some Omicron variants, versus the original novel coronavirus - although whether that translates into stronger protection against serious disease is unclear.
1More

Pharmanovia collaborates with Aquestive Therapeutics for diazepam buccal film - Latest ... - 0 views

  •  
    Pharmanovia, the lifecycle management company has signed a licence and supply agreement with Aquestive Therapeutics for its patented diazepam buccal film formulation across the EU, UK, Switzerland, and Norway, as well as countries in the Middle East and North Africa (MENA)- up to 48 markets in total. Aquestive Therapeutics has been granted tentative approval by the US Food and Drug Administration (FDA), for its diazepam buccal film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older. Pharmanovia will be responsible for seeking appropriate regulatory approval across EU and MENA. Pharmanovia CEO, James Burt commented: "Pharmanovia and Aquestive are aligned in our mission to find new and innovative ways to enhance and revitalise iconic medicines. We have extensive experience with diazepam through the Valium brand and, together with Aquestive's unique PharmFilm technology, we're intending to bring a novel alternative diazepam delivery option to caregivers and patients at a time of critical need."
1More

Rosemont strengthens with acquisition of Lucis Pharma - 0 views

  •  
    Rosemont Pharmaceuticals (Rosemont) has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in the UK. Through this acquisition Rosemont will expand its existing portfolio and have access to a pipeline of innovative products, providing lifesaving pharmaceuticals to the UK and overseas markets. Founded in 2012, Lucis has grown to become a leading provider in the development and licensing of novel and exclusive medicines. With over a dozen SKUs covering a variety of therapeutic areas, Lucis has established a strong portfolio that, in addition to a pipeline of innovative developments, serve the growing patient need for liquid medicines. The acquisition will enable Rosemont to broaden its portfolio and enter the unit dose / sachet market through the pipeline products, whilst growing the business through recent Lucis product launches in 2021/22. "As well as continuing to broaden our portfolio and add to our strong growth globally, this acquisition also gives access to pipeline products and developer relationships to accelerate our entry into new product areas such as sachets" said Howard Taylor, Chief Executive Officer of Rosemont.
1More

https://www.pharmacy.biz/news/uk-govt-to-invest-100m-for-developing-ai-powered-solution... - 0 views

  •  
    The UK Government is investing £100 million to accelerate the use of AI in life sciences and healthcare under a new mission. UK Prime Minister Rishi Sunak announced the AI Life Sciences Accelerator Mission in his speech last week. The new initiative will capitalise on the UK's unique strengths in securing "health data and cutting-edge AI." It will also help to identify those at risk of "dementia" and will ensure that patients participate in the trials at the right time to develop new treatments effectively. Henceforth, it will provide us with better data on how well new therapies work. Sunak said: "AI can help us solve some of the greatest social challenges of our time. AI could help find novel dementia treatments or develop vaccines for cancer."
1More

GSK to buy Affinivax for up to $3.3 bln in vaccines push - 0 views

  •  
    GlaxoSmithKline on Tuesday (May 31) snapped up US biopharmaceutical firm Affinivax for up to $3.3 billion, expanding further into vaccines before the demerger of its consumer health care arm. The London-listed company has agreed to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones for Affinivax. "GSK plc today announced that it has entered into a definitive agreement to acquire Affinivax, Inc," it said in a statement. "Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines," it added. The Cambridge, Massachusetts-based firm specialises in vaccines for diseases including meningitis, pneumonia and bloodstream infections. "The proposed acquisition further strengthens our vaccines research and development (R&D) pipeline, provides access to a new, potentially disruptive technology, and broadens GSK's existing scientific footprint in the Boston area," said GSK's chief scientific officer Hal Barron.
1More

PANORAMIC Study: Pharmacy Teams Encouraged To Support - 0 views

  •  
    Pharmacy teams are being encouraged to support the ground-breaking Platform Adaptive trial of Novel antivirals for early treatment of Covid-19 In the Community (PANORAMIC) study by raising awareness among patients. The study aims to find out whether new antiviral treatments can help Covid-19 patients avoid hospital admission and support a quicker recovery. The PANORAMIC trial will allow researchers to gather data on the potential benefits of treatments to patients and will help the NHS to develop plans for rolling out the products to further patients in 2022. Anyone over the age of 50 or between 18 to 49 with certain underlying health conditions can participate in the trial after receiving a positive PCR or lateral flow test result for Covid-19. People who wish to participate in the trial can sign up themselves through the study's website and may be contacted by a member of the clinical team in a general practice that has been set up to deliver the PANORAMIC trial.
1More

Over 5000 People Enrolled For PANORAMIC Study For Antivirals - 0 views

  •  
    More than 5,000 vulnerable people have enrolled for the ground-breaking Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC) study on life-saving antivirals. With this the UK is now one step closer to rolling out the innovative medicines, which would help reduce the severity of symptoms and the risk of hospitalisation or death. Success of the study would eventually help to ease pressures on the NHS. Anyone over the age of 50 or between 18 to 49 with certain underlying health conditions can participate in the trial after receiving a positive PCR or lateral flow test result.
1More

Innovative Medicines Fund : £340m NHS fund - 0 views

  •  
    The Department of Health and Social Care (DHSC) launched a new Innovative Medicines Fund on Tuesday (June 7) under which £340 million has been made available to purchase potentially life-saving drugs early. This will allow NHS patients in England to have early access to potentially life-saving and cutting-edge treatments Health secretary Sajid Javid said: "I want NHS patients to be the first in the world to access the most promising and revolutionary treatments that could extend or save their lives. "The launch of the Innovative Medicines Fund delivers another manifesto pledge and will fast-track cutting-edge medicines to adults and children to give people renewed hope for a better future." A total of £680 million has been ringfenced for the Innovative Medicines Fund and Cancer Drugs Fund - £340 million each - to fast-track medicines to NHS patients. DHSC said: "The Innovative Medicines Fund will provide quick access to novel treatments, including potentially lifesaving gene therapies for serious conditions with few treatment options. It often takes longer for pharmaceutical companies to collect data on a medicine's clinical and cost effectiveness for rare diseases due to the smaller patient cohort.
1More

Chiesi Farmaceutici acquires Amryt Pharma - 0 views

  •  
    Chiesi Farmaceutici, the international, research-focused biopharmaceuticals and healthcare group has acquired Amryt Pharma, a global biopharmaceutical company dedicated to developing novel treatments for rare diseases. More than 300 million people worldwide are affected by rare diseases, including those who are living with ultra-rare metabolic and dermatologic conditions who still have no approved treatment. The acquisition reinforces Chiesi's commitment to deliver innovative treatments to patients with highly unmet medical needs. As a benefit corporation and a B Corp, Chiesi strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. Chiesi's Head of Chiesi Global Rare diseases Giacomo Chiesi commented: "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to rare diseases and aligns with our growth strategy through partnerships beyond internal research and development." Chiesi's new CEO Giuseppe Accogli said: "By joining forces and expertise we will be able to grow our capabilities and further strengthen our position to provide a positive impact on patients living with rare diseases." With regard to the financing of the deal, cash consideration has been partially financed through a EUR 700m syndicated loan led by BNP Paribas and Crédit Agricole as Global Coordinators and ESG Structuring Banks, acting alongside BPER and Deutsche Bank as Mandated Lead Arrangers. Crédit Agricole is Loan Agent too. Lenders have been advised by Clifford Chance, while Baker and McKenzie has assisted Chiesi Farmaceutici.
1More

Meet Dr. Amira Guirguis RPS's New Science Committee Chair - 0 views

  •  
    The Royal Pharmaceutical Society (RPS) has appointed Dr Amira Guirguis as the new Chair of its Science and Research Committee, effective from the New Year. An accomplished pharmacist and renowned expert in substance misuse, Dr Guirguis was nominated by the RPS as a 'woman to watch' in 2020. Previously, she has served as the Principal Investigator for the first Home Office-licensed Pharmacist-led drug checking service in the UK, and as the MPharm Programme Director at Swansea University Medical School. A PhD in Novel Psychoactive Substances (NPS) detection, she has made significant contributions to the field of pharmacy, to drug policy, and has won the 2014 JPAG Geoffrey Phillips award for her groundbreaking research.
1More

Safer Polio Vaccine NOPS2 Now Globally Available - 0 views

  •  
    The Medicines and Healthcare products Regulatory Agency (MHRA) on Wednesday (9 January) announced that the novel type 2 oral polio vaccine (nOPV2) has been quality-assured (prequalified) by the World Health Organization (WHO). Developed by a team including scientists from the MHRA, nOPV2 is considered a safer polio vaccine that helps to protect children from the disabling and life-threatening disease and lower the risk of vaccine-derived outbreaks. The vaccine received WHO Emergency Use Listing three years ago, and since then 950 million doses have been delivered worldwide. The UN health agency's decision to add it to the list of prequalified vaccines is based on the analysis of outcomes in vaccinated populations that has confirmed strong safety profile and effectiveness.
1More

Restore Your Vision with Corneal Transplant surgery - 1 views

  •  
    Restore Your Vision with Corneal Transplant surgery In circumstances where blurriness takes place in the cornea there is basically no other way to cure it other than Cornea transplant treatment. This surgery restores the damaged cornea with a novel healthy tissue. Another ordinary name for this treatment is corneal graft or penetrating keratoplasty.
1More

CorneaUSA - 1 views

  •  
    In circumstances where blurriness takes place in the cornea there is basically no other way to cure it other than Cornea transplant treatment. This surgery restores the damaged cornea with a novel healthy tissue. Another ordinary name for this treatment is corneal graft or penetrating keratoplasty.
1 - 20 of 22 Next ›
Showing 20 items per page